Global Prefilled Syringes Market was valued at US$ 1,432.2 million in 2020 and is anticipated to reach US$ 3,301.1 million by 2027 displaying an elevated CAGR of 10% over the forecast period ...

with management highlighting differentiated profiles for MariTide and Repatha as mitigating factors. Amgen’s Q1 2025 earnings call highlighted strong revenue and volume growth, driven by key ...

Amgen Inc (NASDAQ:AMGN) launched three new products or indications and initiated four new Phase 3 studies, demonstrating robust pipeline progress. Repatha sales increased by 27% year over year ...

(Reuters) -Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to speculate on the impact of U.S. tariffs, tax policy would be a ...

Fourteen products delivered at least double-digit sales growth in the quarter, including Repatha, BLINCYTO, and TEZSPIRE. The company’s newly launched IMDELLTRA generated $81 million in sales. For the ...

THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first ...

Amgen Inc. reported better-than-expected earnings for the first quarter of 2025, with earnings per share (EPS) of $4.90 surpassing the forecast of $4.29. The company also exceeded revenue expectations ...

Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options ... Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer ...

Amgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Kyprolis and Blincyto among others. However, prices of most products are expected to ...

The upcoming report from Amgen (AMGN) is expected to reveal quarterly ... According to the collective judgment of analysts, 'Product Sales- Repatha- Total' should come in at $616.47 million.